Hardy J. Rideout, PhD

Dr. Hardy Rideout is based in the neurodegenerative diseases lab at the Biomedical Research Foundation of the Academy of Athens. His recent work has focused on developing novel quantitative assays for measuring LRRK2 pathway signaling in clinical biosamples from people with Parkinson’s disease (PD). Such assays are critical for the stratification of trial participants and for monitoring therapeutics that target LRRK2 activity, such as small molecule kinase inhibitors. Related to this, Dr. Rideout’s work is also aimed at uncovering the regulation of LRRK2 activation via protein interactions and how this impacts PD pathogenesis and progression in different cell types. Finally, another major aspect of Dr. Rideout is characterizing the activation of neuronal cell death pathways that are modulated by mutant forms of LRRK2 in both cellular and preclinical models of PD.